Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder

Brain, Behavior, and Immunity

Volumn 46, Issue , 2015, Pages 55-59

  Savitz, Jonathan ^a,b   Drevets, Wayne C ^c   Wurfel, Brent E ^a,d   Ford, Bart N ^a   Bellgowan, Patrick S F ^a,b   Victor, Teresa A ^a   Bodurka, Jerzy ^a,e   Teague, T Kent ^d,f,g   Dantzer, Robert ^h  

^a LAUREATE INSTITUTE FOR BRAIN RESEARCH   (United States)

^b UNIVERSITY OF TULSA   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^d University of Oklahoma Tulsa College of Medicine   (United States)

^e UNIVERSITY OF OKLAHOMA   (United States)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

^g OKLAHOMA STATE UNIVERSITY   (United States)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anhedonia; Inflammation; Kynurenic acid; Kynurenine; Major depressive disorder; Quinolinic acid; Remission

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; KYNURENIC ACID; KYNURENINE; QUINOLINIC ACID;

AMINO ACID BLOOD LEVEL; ANHEDONIA; ARTICLE; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEPRESSION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFLAMMATION; MAJOR DEPRESSION; MALE; METABOLISM; METABOLITE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; TANDEM MASS SPECTROMETRY; ADOLESCENT; ADULT; BLOOD; LIQUID CHROMATOGRAPHY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; CHROMATOGRAPHY, LIQUID; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; KYNURENIC ACID; MALE; MIDDLE AGED; QUINOLINIC ACID; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84928824523     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.02.007     Document Type: Article

References (35)

1. Amaral M., Levy C., Heyes D.J., Lafite P., Outeiro T.F., Giorgini F., Leys D., Scrutton N.S. Structural basis of kynurenine 3-monooxygenase inhibition. Nature 2013, 496:382-385.
2. Bay-Richter C., Linderholm K.R., Lim C.K., Samuelsson M., Traskman-Bendz L., Guillemin G.J., Erhardt S., Brundin L. A role for inflammatory metabolites as modulators of the glutamate N-methyl-d-aspartate receptor in depression and suicidality. Brain Behav. Immun. 2015, 43:110-117.
3. Dahl J., Ormstad H., Aass H.C., Malt U.F., Bendz L.T., Sandvik L., Brundin L., Andreassen O.A. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014, 45:77-86.
4. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
5. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
6. Frommberger U.H., Bauer J., Haselbauer P., Fraulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 1997, 247:228-233.
7. Gold P.W., Pavlatou M.G., Carlson P.J., Luckenbaugh D.A., Costello R., Bonne O., Csako G., Drevets W.C., Remaley A.T., Charney D.S., Neumeister A., Kling M.A. Unmedicated, remitted patients with major depression have decreased serum immunoglobulin A. Neurosci. Lett. 2012, 520:1-5.
8. Guidetti P., Schwarcz R. 3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?. Adv. Exp. Med. Biol. 2003, 527:137-145.
9. Hamer M., Batty G.D., Marmot M.G., Singh-Manoux A., Kivimaki M. Anti-depressant medication use and C-reactive protein: results from two population-based studies. Brain Behav. Immun. 2011, 25:168-173.
10. Hannestad J., DellaGioia N., Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011, 36:2452-2459.
11. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
12. Johansson A.S., Owe-Larsson B., Asp L., Kocki T., Adler M., Hetta J., Gardner R., Lundkvist G.B., Urbanska E.M., Karlsson H. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J. Psychiatr. Res. 2013, 47:1815-1823.
13. Kaddurah-Daouk R., Yuan P., Boyle S.H., Matson W., Wang Z., Zeng Z.B., Zhu H., Dougherty G.G., Yao J.K., Chen G., Guitart X., Carlson P.J., Neumeister A., Zarate C., Krishnan R.R., Manji H.K., Drevets W. Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci. Rep. 2012, 2:667.
14. Kling M.A., Alesci S., Csako G., Costello R., Luckenbaugh D.A., Bonne O., Duncko R., Drevets W.C., Manji H.K., Charney D.S., Gold P.W., Neumeister A. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol. Psychiatry 2007, 62:309-313.
15. Maes M., Vandoolaeghe E., Ranjan R., Bosmans E., Bergmans R., Desnyder R. Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J. Affect. Disord. 1995, 36:29-36.
16. Maes M., Galecki P., Verkerk R., Rief W. Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol. Lett. 2011, 32:264-273.
17. Maes M., Berk M., Goehler L., Song C., Anderson G., Galecki P., Leonard B. Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 2012, 10:66.
18. Manji H.K., Drevets W.C., Charney D.S. The cellular neurobiology of depression. Nat. Med. 2001, 7:541-547.
19. McCabe C., Cowen P.J., Harmer C.J. Neural representation of reward in recovered depressed patients. Psychopharmacology 2009, 205:667-677.
20. Miller A.H., Haroon E., Raison C.L., Felger J.C. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety 2013, 30:297-306.
21. Myint A.M., Kim Y.K. Cytokine-serotonin interaction through IDO: a neurodegeneration hypothesis of depression. Med. Hypotheses 2003, 61:519-525.
22. Myint A.M., Kim Y.K., Verkerk R., Scharpe S., Steinbusch H., Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect. Disord. 2007, 98:143-151.
23. Narita K., Murata T., Takahashi T., Kosaka H., Omata N., Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:1159-1162.
24. Ogawa T., Matson W.R., Beal M.F., Myers R.H., Bird E.D., Milbury P., Saso S. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 1992, 42:1702-1706.
25. Pechtel P., Dutra S.J., Goetz E.L., Pizzagalli D.A. Blunted reward responsiveness in remitted depression. J. Psychiatr. Res. 2013, 47:1864-1869.
26. Rahman A., Ting K., Cullen K.M., Braidy N., Brew B.J., Guillemin G.J. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One 2009, 4:e6344.
27. Savitz J., Dantzer R., Wurfel B.E., Victor T.A., Ford B.N., Bodurka J., Bellgowan P.S., Teague T.K., Drevets W.C. Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology 2014, 52C:200-211.
28. Savitz J.B., Price J.L., Drevets W.C. Neuropathological and neuromorphometric abnormalities in bipolar disorder: view from the medial prefrontal cortical network. Neurosci. Biobehav. Rev. 2014, 42:132-147.
29. Savitz J., Drevets W.C., Smith C.M., Victor T.A., Wurfel B.E., Bellgowan P.S., Bodurka J., Teague T.K., Dantzer R. Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 2015, 40:463-471.
30. Schwarcz R., Bruno J.P., Muchowski P.J., Wu H.Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 2012, 13:465-477.
31. Stone T.W., Forrest C.M., Darlington L.G. Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection. FEBS J. 2012, 279:1386-1397.
32. Victor T.A., Furey M.L., Fromm S.J., Ohman A., Drevets W.C. Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch. Gen. Psychiatry 2010, 67:1128-1138.
33. Vogelgesang S.A., Heyes M.P., West S.G., Salazar A.M., Sfikakis P.P., Lipnick R.N., Klipple G.L., Tsokos G.C. Quinolinic acid in patients with systemic lupus erythematosus and neuropsychiatric manifestations. J. Rheumatol. 1996, 23:850-855.
34. Vogelzangs N., Duivis H.E., Beekman A.T., Kluft C., Neuteboom J., Hoogendijk W., Smit J.H., de Jonge P., Penninx B.W. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl. Psychiatry 2012, 2:e79.
35. Yirmiya R., Pollak Y., Morag M., Reichenberg A., Barak O., Avitsur R., Shavit Y., Ovadia H., Weidenfeld J., Morag A., Newman M.E., Pollmacher T. Illness, cytokines, and depression. Ann. N. Y. Acad. Sci. 2000, 917:478-487.